Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

3,762

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

3,762 results for “Combination treatment”

Learn how ShareScore rates datasets ↗
dryad36/100

Modelling data for: Short-course combination treatment for experimental chronic Chagas disease

<p><span>Chagas disease, caused by the protozoan parasite <em>Trypanosoma</em> <em>cruzi</em>, affects millions of people in the Americas and across the world leading to considerable morbidity and mortality. Current treatment options, benznidazole (BNZ) and nifurtimox, offer limited efficacy and often lead to adverse side effects due to long treatment durations. Better treatment options are therefore urgently required. Here we describe a pyrrolopyrimidine series, identified through phenotypic screening, that offers a clear opportunity to improve on current treatments. In vitro cell-based washout assays demonstrate that compounds in the series are incapable of killing all parasites, however, combining these pyrrolopyrimidines with a sub-efficacious dose of BNZ can clear all parasites in vitro after five days. Importantly, these findings were replicated in a clinically predictive<em> in vivo</em> model of chronic Chagas disease, where five days of treatment with the combination was sufficient to prevent parasite relapse. Comprehensive mechanism of action studies, supported by ligand-structure modelling, show that compounds from this pyrrolopyrimidine series inhibit the Q</span><sub><span>i</span></sub><span> active site of <em>T. cruzi</em> cytochrome <em>b</em>, part of the cytochrome <em>bc1</em> complex of the electron transport chain. Knowledge of the molecular target enabled a cascade of assays to be assembled to evaluate selectivity over the human cytochrome <em>b</em> homologue. As a result, a highly selective and efficacious lead compound was identified. The combination of our lead compound with BNZ rapidly clears<em> T. cruzi</em> parasites, both <em>in vitro</em> and <em>in vivo</em>, and shows great potential to overcome key issues associated with currently available treatments.  </span></p>

opencc-zeroDec 2023View details →
zenodo36/100

Effects of treatment by synthetic strigolactone (SL) on WUE and NUE in two tomato varieties under normal and combined-stress conditions

<p>The present work aims to analyse the influence of strigolactones (SL) on WUE and NUE under combined stress (drought and phosphate deprivation) in two tomato TOMRES varieties. One variety was chosen because it was found to be less sensitive to nitrogen starvation (# 250) by UNA, while the other (# 270) is more or less as sensitive as the wild type used in previous experiments (M82).</p>

opencc-by-4.0Jun 2021View details →
zenodo36/100

Dataset for comparison of the efficacy of different drug combinations for the treatment of patients with triple negative breast cancer.

<p>Dataset for comparison of the efficacy of different drug combinations for the treatment of patients with triple negative breast cancer.</p>

opencc-by-4.0Nov 2022View details →
ClinicalTrials.gov36/100

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

ClinicalTrials.gov study NCT00995488. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Combined Treatment for Mixed Incontinence

ClinicalTrials.gov study NCT01959347. IPD Sharing: NO. Countries: 1. Publications: 4.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain

ClinicalTrials.gov study NCT01559259. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

ClinicalTrials.gov study NCT03982186. IPD Sharing: YES. Countries: 19. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

ClinicalTrials.gov study NCT01422876. IPD Sharing: Not stated. Countries: 22. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension

ClinicalTrials.gov study NCT00797862. IPD Sharing: Not stated. Countries: 10. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

ClinicalTrials.gov study NCT00111839. IPD Sharing: Not stated. Countries: 3. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Non-Invasive Brain-Computer Interface Combined With Transcranial Electrical Stimulation for Peripheral Facial PalsyStimulation in the Treatment of Peripheral Facial Palsy

ClinicalTrials.gov study NCT07327710. IPD Sharing: NO. Countries: 1. Publications: 7.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

ClinicalTrials.gov study NCT02403778. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

ClinicalTrials.gov study NCT00937560. IPD Sharing: Not stated. Countries: 9. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

ClinicalTrials.gov study NCT01435759. IPD Sharing: Not stated. Countries: 5. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

ClinicalTrials.gov study NCT00001521. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment

ClinicalTrials.gov study NCT00632749. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)

ClinicalTrials.gov study NCT01343888. IPD Sharing: Not stated. Countries: 11. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

ClinicalTrials.gov study NCT04340843. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan

ClinicalTrials.gov study NCT00603512. IPD Sharing: Not stated. Countries: 1. Publications: 13.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

ClinicalTrials.gov study NCT01732796. IPD Sharing: Not stated. Countries: 14. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record